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Abstract
Background: In hereditary spherocytosis with severe anemia, splenectomy is a recommended treatment. However, the
spleen carries an important role both in immune function and coagulation. The increased risk of bacterial infections
associated with splenectomy is well known. Recently, hypercoagulation disorders have also been linked to splenectomy
through loss of regulation of platelet activity, loss of filtering function and post-splenectomy thrombocytosis.
Case presentation: A 28 year-old smoking women who had previously undergone splenectomy due to hereditary
spherocytosis with a moderate thrombocytosis (platelet count 553–635*109/L), presented with recurrent episodes of
pulmonary embolisms. Further examination by multimodality cardiac imaging demonstrated a giant chronic thrombus
in the right ventricular outflow tract, which eventually had to be surgically removed.
Conclusions: The present case highlights the increased risk of severe thromboembolic complications following
therapeutic splenectomy in hereditary spherocytosis, and emphasis the important role of multimodality cardiac imaging
in recurrent pulmonary embolism, diagnosing a giant chronic thrombus in the right ventricular outflow tract.
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Background
Hereditary spherocytosis is a genetic disease affecting
membrane proteins of the erythrocytes responsible for
interactions with the cytoskeleton. This leads to loss of
the biconcave disk shape and results in spheric erythro-
cytes. These abnormal erythrocytes are removed by the
spleen leading to various degrees of hemolytic anemia
[1]. In patients with severe hemolytic anemia, splenec-
tomy is very effective in reducing hemolysis, but it is as-
sociated with an increased risk of infections, particularly
those caused by encapsulated bacteria such as Strepto-
coccus pneumoniae and Haemophilus influenza [2]. In
addition to bacterial infections, recent publications sug-
gest a link between splenectomy and thromboembolic
complications in patients with spherocytosis [3–9]. In
this case report, we present a young splenectomized
women with hereditary spherocytosis complicated by re-
current pulmonary embolism due to a chronic right
ventricular outflow tract thrombus, which eventually
was surgically removed.
Case presentation
A 28 year old woman with hereditary spherocytosis who
had undergone splenectomy at the age of 11 was admit-
ted to a local hospital with hemoptysis and abdominal
pain. The diagnosis hereditary spherocytosis, was based
on family history, anemia and detection of spherocytes,
the diagnosis has not been re-confirmed by eosin-5-
maleimide (EMA) binding test in the recent past, and no
mutation testing has been performed. Blood tests revealed
leukocytosis (White blood cell count 18.5-16.8*109/L),
normal C-reactive protein and elevated D-dimer. The
hemoglobin level was normal (14.6–15.0 g/dL), but sphero-
cytes was noticed in the blood smear. A mild thrombocytosis
(platelet count during hospital stays differed between 553–
635*109/L) was noticed. Due to the elevated D-dimer a hel-
ical computer tomography (CT) pulmonary angiography
was performed, which revealed no pulmonary embolism, but
a lung consolidation in the lateral part of the left inferior
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lobe, interpreted as pneumonia, and the patient was treated
with antibiotics.
A year later the patients was re-admitted for a new
episode of hemoptysis. A second helical CT-pulmonary
angiography was performed, showing a consolidation in
the right inferior lobe (Fig. 1) and suspicion of a
thrombus in the right ventricle (Fig. 2). The lung con-
solidation was interpreted as a pulmonary infarction due
to pulmonary embolism from the cardiac thrombus.
Consequently, anticoagulation therapy with low-molecular
weight heparin followed by warfarin was initiated. Apart
from being a smoker, the medical history did not identify
any classic risk factor for pulmonary embolism. In particu-
larly, no family history of thrombosis, obesity, use of con-
traceptives, immobilization or recent long flights, injury or
surgery associated with increased risk of thrombosis was
present. No thrombophilic disorders (protein S deficiency,
protein C deficiency, Factor V Leiden/activated protein C
resistance, antithrombin (AT III) deficiency) were identified
on blood tests. Antiphospholipid antibodies, lupus anti-
coagulant, anti-kardiolipin and anti-beta2-glycoprotein 1
were all negative, homocystein analysis was not performed.
No clinical sign of inflammatory or malignant disease was
identified during the diagnostic work-up, except for å mild
leukocytosis and thrombocytosis that was regarded to be
part of the thrombotic disease and previous splenectomy.
A supplemental bone marrow biopsy to rule out any mye-
lodysplastic syndrome was not performed as the patient
was unwilling.
After 6 months of continuous anticoagulation therapy,
the patient was readmitted for the third time due to short-
ness of breath and hemoptysis. A new CT pulmonary
angiography showed multiple pulmonary embolisms and a
persistent structure in the right ventricle. Multimodality
imaging of the intracavitary cardiac structure was then
performed. Transthoracic echocardiography revealed an
elongated highly mobile structure attached to the right
ventricular septum extending through the right ventricle
outflow tract and into the pulmonary trunk (Fig. 3, panel
a, Additional file 1). Supplemental contrast-enhanced im-
aging revealed no contrast uptake in the structure, consist-
ent with a large right ventricular thrombus (Fig. 3, panel
b, Additional file 2). Cardiac magnetic resonance imaging
(MRI) confirmed an approximately 7 cm long thrombus
attached to the apical part of the right ventricular septum
protruding through the pulmonary valve in systole, but
retracting to just below the pulmonary valve in diastole
(Fig. 4, Additional file 3). Due to persistence of the
thrombus and recurrent pulmonary embolism despite
adequate anticoagulation therapy, surgical removal was
performed, and the thromboembolic nature of the excised
structure was confirmed by pathological examination.
Postoperatively, long-term treatment with low- molecular
- weight heparin injections was recommended. Echocardi-
ography 6 months postoperatively was normal.
Recently, it has been acknowledged that splenectomy in
hereditary spherocytosis is associated with a significant in-
creased long-term risk of venous thromboembolic events,
and severe chronic thromboembolic pulmonary hyperten-
sion has been reported in patients with hereditary sphero-
cytosis after splenectomy [6, 7, 9, 10]. The current case
adds to these by demonstrating a giant thrombus in the
right ventricle as source for recurrent pulmonary infarc-
tions despite adequate anticoagulation therapy, in a patient
with hereditary spherocytosis and previous splenectomy, in
which smoking was the only classic risk factor for increased
thrombosis risk detected during the diagnostic work-up. A
possible mechanism for the observed thrombosis risk after
splenectomy is loss of splenic regulation of platelet activity
and clearing of platelets from the bloodstream resulting in
a post-splenectomy thrombocytosis and the loss of filter
Fig. 1 Thoracic CT-scan showing a consolidation in the right inferior
lobe (arrow) interpreted as a pulmonary infarction due to pulmonary
embolism from the cardiac thrombus
Fig. 2 CT-pulmonary angiography that aroused suspicion of a thrombus
in the right ventricle (arrow)
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function in the spleen leading to an accumulation of pro-
thrombotic blood elements [11]. The present case under-
lines that the benefit of splenectomy in reducing hemolysis
in hereditary spherocytosis should be weighed against the
increased long-term risk of severe thromboembolism and
severe infections [12]. More recently, partial splenectomy is
emerging as a possible treatment option to overcome these
complications, although long-term data on infection and
vascular risk are still lacking [13].
The impact of splenectomy on the increased thrombo-
embolic risk was demonstrated in a prospective observa-
tional study of 634 patients from families with hereditary
spherocytosis, followed from 1960 to 2007, finding patients
who underwent splenectomy to have a 3-fold increased
rate of thrombotic events compared to those who did not
[8]. Nevertheless, current guidelines do not recommend
extended thrombosis prophylaxis after splenectomy in pa-
tients with hereditary spherocytosis [1]. In our patient,
apart from being a smoker, no other precipitating cause for
pulmonary embolism was identified, and thus we believe it
was caused by the splenectomy-associated risk for throm-
bosis. In an experimental study in mice splenectomy was
associated with larger and more persistent thrombi and de-
layed thrombus resolution during anticoagulation therapy,
paralleling the findings in our clinical case [11].
Right ventricular thrombi are present in approximately
4 % of patients with pulmonary embolisms, and are asso-
ciated with a high mortality [14]. Although the current
ESC guidelines on pulmonary embolism [15] does not
warrant routine echocardiography in clinically stable pa-
tients with pulmonary embolism, repeated pulmonary
embolisms and a suspected right ventricular thrombus on
CT pulmonary angiography at the second hospitalization
should have prompted additional cardiac imaging at an
earlier point of time in our case and possibly a more
aggressive treatment strategy.
Management of right ventricular thrombi is challenging.
The three therapeutic options for right heart thrombus
are anticoagulation, thrombolysis or surgical thrombec-
tomy. The optimal management is undocumented, since
randomized controlled trials are lacking. Observational
studies have reported comparable mortality for the three
treatment options, 20–25 % after 14 days [14, 16, 17]. In
contrast, a retrospective meta-analysis of 177 cases pub-
lished between 1966 and 2000 the mortality was lower
with thrombolysis (11 %) than with surgery (24 %) or
anticoagulation (29 %) [18].
The European Cooperative Study on the clinical signifi-
cance of right heart thrombi suggested a thrombus classifi-
cation system for individualization of treatment [19]. Type
A, extremely mobile thrombi in structurally normal hearts,
are believed to originate in peripheral veins, and merely
transit in the heart. Type B are immobile and though to
originate within the right heart chambers, while type C
thrombi elicit intermediate characteristics of both type A
and B. While type A has been associated with high early
mortality from massive pulmonary embolism and requires
Fig. 3 Transthoracic echocardiography showing a giant right intra-ventricular structure (arrow) in a parasternal short axis view (Panel a). The
characteristic lack of contrast enhancement in the right intra-ventricular cavity confirms the presence of a giant right ventricular thrombus
(Panel b)
Fig. 4 Cardiac magnetic resonance imaging in a sagittal plane
demonstrating the piston-like shape of the thrombus, and how it
protrudes through the pulmonary valve in systole
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aggressive therapy, type B has a more benign course and
can be managed with anticoagulation. In our patient with a
type C thrombus who already had received six months of
anticoagulation therapy, anticoagulation alone was not a
therapeutic option, and thrombolysis of such a large
thrombus carried high risk of fragmentation and further
occlusion of pulmonary arteries. The patient was young
with low operative risk, favoring surgical removal of the
thrombus. Following surgery, long-term anticoagulation
treatment was indicated to avoid new thromboembolic epi-
sodes. As the patient had experienced recurrent pulmonary
embolism during anticoagulation therapy with warfarin,
long-term anticoagulation treatment with low-molecular-
weight heparin was initiated, as the treatment can be easily
monitored by antiXa and the treatment effect is well docu-
mented for instance in cancer patients [20]. After 1 year,
changing to warfarin in combination with aspirin will be
considered [21, 22].
Conclusion
The present case demonstrates the increased risk of severe
thromboembolic complications following therapeutic splen-
ectomy in hereditary spherocytosis, and the role of echocar-
diography and multimodality cardiac imaging in diagnosis
of right ventricular thrombus as the cause of repeated
pulmonary embolism.
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